Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
Androstenes
/ therapeutic use
Antineoplastic Agents
/ therapeutic use
Benzamides
/ therapeutic use
Black People
/ statistics & numerical data
Docetaxel
/ therapeutic use
Guadeloupe
/ epidemiology
Humans
Male
Middle Aged
Neoplasm Metastasis
/ diagnosis
Neoplasm Staging
Nitriles
/ therapeutic use
Phenylthiohydantoin
/ therapeutic use
Progression-Free Survival
Prostate-Specific Antigen
/ blood
Prostatic Neoplasms, Castration-Resistant
/ blood
Retrospective Studies
Treatment Outcome
abiraterone
docetaxel
enzalutamide
mCRPC
prostate cancer
survival
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
19
10
2021
received:
20
08
2021
accepted:
09
11
2021
pubmed:
26
11
2021
medline:
22
2
2022
entrez:
25
11
2021
Statut:
ppublish
Résumé
Several studies in the Caucasian population have shown the benefit of using docetaxel, abiraterone, or enzalutamide for patients with metastatic prostate cancer at the castration-resistant stage (mCRPC). However, there are no strong data for men of African ancestry. The objective of this study was to estimate the overall and progression-free survival of patients according to these treatments at the mCRPC stage. This was a monocentric retrospective study that consecutively included 211 men with mCRPC between June 1, 2009 and August 31, 2020. The primary end point was overall survival (OS). The secondary end point was progression-free survival. Kaplan-Meier survival and Cox proportional hazard analyses were performed. The present study included 180 patients for analyses. There was no difference in OS (log-rank test = 0.73), with a median follow-up of 20.7 months, regardless of the treatment administered in the first line. Men with mCRPC who received hormonotherapy (abiraterone or enzalutamide) showed better progression-free survival than those who received docetaxel (log-rank test = 0.004), with a particular interest for abiraterone hazard ratio (HR) = 0.51 (95% confidence interval: 0.39-0.67). The patient characteristics were similar, except for bone lesions, irrespective of the treatment administered in the first line. After univariate then multivariate analysis, only World Health Organization status and metastases at diagnosis were significantly associated with progression. Our results suggest the use of hormonotherapy (abiraterone or enzalutamide) with a tendency for abiraterone in first line for men with African ancestry at the mCRPC stage.
Substances chimiques
Androstenes
0
Antineoplastic Agents
0
Benzamides
0
Nitriles
0
Docetaxel
15H5577CQD
Phenylthiohydantoin
2010-15-3
enzalutamide
93T0T9GKNU
Prostate-Specific Antigen
EC 3.4.21.77
abiraterone
G819A456D0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
269-275Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63-89.
Données du registre général des cancers de Guadeloupe [Internet]. Accessed November 17, 2021. https://lesdonnees.e-cancer.fr/Fiches-Indicateurs/Registre-General-des-cancers-de-la-Guadeloupe#donnees
La morbidité compétitive et son impact sur l'espérance de vie: évaluation et prise en compte dans la décision thérapeutique du cancer localisé de la prostate. 2018. Accessed November 17, 2021. https://www.urofrance.org/base-bibliographique/la-morbidite-competitive-et-son-impact-sur-lesperance-de-vie-evaluation-et
Leslie SW, Soon-Sutton TL, Sajjad H, Siref LE. Prostate Cancer. StatPearls Publishing; 2021.
Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119-1134.
Rozet F, Hennequin C, Beauval J-B, et al. RETRACTED: recommandations françaises du Comité de Cancérologie de l'AFU-Actualisation 2018-2020: cancer de la prostate. Prog En Urol. 2018;28(12):S79-S130.
Cornford P, van den Bergh R, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263-282.
Singh SK, Lillard JW, Singh R. Molecular basis for prostate cancer racial disparities. Front Biosci. 2017;22:428-450.
RECIST_1.1.pdf [Internet]. Accessed November 17, 2021. http://www.cepd.fr/CUSTOM/RECIST_1.1.pdf
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152-160.
Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983-992.
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197. doi:10.1056/NEJMoa1207506
Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424-433.
de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-1154.
Meunier ME, Blanchet P, Neuzillet Y, Lebret T, Brureau L. A review of new hormonal therapies for prostate cancer in black men: is there enough data? BMC Cancer. 2021;21:61.
Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737-746.
Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29(5):1235-1248.
Leuva H, Sigel K, Zhou M, et al. A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on veterans treated with abiraterone and enzalutamide. Semin Oncol. 2019;46(4-5):351-361.
Van Soest RJ, Van Royen ME, de Morrée ES, et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer. 2013;49(18):3821-3830.
van Soest RJ, de Morrée ES, Kweldam CF, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur Urol. 2015;67(6):981-985.
de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381(26):2506-2518.
Delanoy N, Hardy-Bessard A-C, Efstathiou E, et al. Sequencing of taxanes and new androgen-targeted therapies in metastatic castration-resistant prostate cancer: results of the international multicentre retrospective CATS database. Eur Urol Oncol. 2018;1(6):467-475.
Robinson D, Van Allen EM, Wu Y-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-1228.
Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697-1708.
Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):162-174.